Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Lymphoma, Hodgkin
  • Lymphoma Non-Hodgkin
Design
Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age
Between 20 years and 90 years
Gender
Both males and females

Description

The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows. Registration after infor...

The study population is aggressive lymphomas requiring systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled into the study. Patients can be treated according to the principle of routine care of our institute. The study process is as follows. Registration after informed consent. Laboratory and radiological evaluation after registration including collection of serum and cell-free DNA from patients' peripheral blood Interim and final response evaluation including collection of serum and cell-free DNA from patients' peripheral blood Regular monitoring disease status and update of survival status Laboratory and radiological evaluation after relapse or progression including collection of serum and cell-free DNA from patients' peripheral blood

Tracking Information

NCT #
NCT03117036
Collaborators
Samsung Genomic Institute
Investigators
Principal Investigator: Seok Jin Kim, MD, PhD Samsung Medical Center